Tucker Thamizan, Ritter Alison, Maher Claire, Jackson Henry
Turning Point Alcohol and Drug Centre Fitzroy, Victoria, Australia.
Drug Alcohol Rev. 2004 Sep;23(3):299-309. doi: 10.1080/09595230412331289464.
With naltrexone registered only recently in Australia in 1999, it is important to examine the rate of uptake of naltrexone treatment, early attrition and retention rates during treatment, in order to inform the way naltrexone is used in Australian practice. Of 317 people screened for the study, 97 participants were recruited post-withdrawal from opiates and were inducted to naltrexone after a period of at least 5 days of abstinence. While in treatment, participants received a 50-mg dose of naltrexone daily, with daily dispensing for the first 7 days, and weekly dispensing for the following 11 weeks. For the naltrexone-treated sample as a whole, the rate of uptake of naltrexone treatment was 30%, with 30% retained in treatment for the entire 12-week program. Attrition from treatment was found to be steady throughout the 12 weeks. The authors conclude that further research is required to improve withdrawal and naltrexone induction techniques and to improve medication compliance and treatment retention.
纳曲酮于1999年才在澳大利亚注册，因此，研究纳曲酮治疗的采用率、早期脱落率和治疗期间的留存率，对于指导澳大利亚实际使用纳曲酮的方式具有重要意义。在为该研究进行筛查的317人中，97名参与者在停用阿片类药物后被招募，并在至少5天的禁欲期后开始使用纳曲酮。在治疗期间，参与者每天服用50毫克纳曲酮，前7天每天配药，接下来的11周每周配药。对于整个接受纳曲酮治疗的样本，纳曲酮治疗的采用率为30%，在整个12周的疗程中有30%的人持续接受治疗。研究发现，在整个12周内，治疗脱落情况较为稳定。作者得出结论，需要进一步研究以改进戒断和纳曲酮诱导技术，并提高药物依从性和治疗留存率。
